GC Cell and BioCentriq® Execute Process Transfer Agreement in Anticipation of the U.S. entry of Immuncell-LC Inj.
- Written by PR Newswire
![]() |
- Immuncell-LC Inj. is an autologous Cytokine Induced Killer (CIK) cell therapy approved for Commercial use in South Korea as an adjuvant cell therapy for the treatment of Hepatocellular Carcinoma (HCC) after curative resection and has received FDA Orphan Drug Designations (ODDs) for liver, brain, and pancreatic cancers.
- Immuncell-LC Inj. reduced HCC...















